succinate dehydrogenase complex subunit D pseudogene 2Genealiases: []
Q-omics provides the consensus-scored SDHDP2 profile across patient tissues and cancer cell-line models. SDHDP2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, SDHDP2 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, SDHDP2 RNA expression shows 10,935 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight COAD, BRCA, and GBM as cancer lineages where SDHDP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SDHDP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SDHDP2 survival associations across molecular data types. SDHDP2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SDHDP2 RNA expression–survival associations across cancer types. High SDHDP2 expression shows unfavorable associations in BRCA, KIRP, MESO and LGG, but favorable associations in COAD and KIRC. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for SDHDP2 RNA expression.
This table summarizes SDHDP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SDHDP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SDHDP2 shows lower tumor expression in READ, THCA and STAD and higher tumor expression in BRCA, HNSC and LUAD. The BRCA box plot shows higher SDHDP2 RNA expression in tumor versus normal tissue (log2 FC = +0.138, t-test p = .025).
This table shows molecular features associated with SDHDP2 in patient tissues and cancer cell lines. In patient samples, SDHDP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
